US EditionTaiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for ...
Summary by World News
43 Articles
43 Articles
The Courier-Tribune+41 Reposted by 41 other sources
Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
The submission is based on clinical trial data demonstrating that INQOVI in combination with venetoclax met complete response endpoints; no new safety concerns were reportedIf approved, INQOVI in combination with venetoclax would be the first all-oral combination treatment for patients…
Coverage Details
Total News Sources43
Leaning Left5Leaning Right6Center14Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 20%
C 56%
R 24%
Factuality
To view factuality data please Upgrade to Premium
